BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Lonza Opens State-of-the-Art R&D Facility in Slough, UK to Drive Biologics Innovation

Lonza, a global leader in biotechnology and pharmaceutical manufacturing, is proud to announce the opening of its new state-of-the-art research and develop...

December 19, 2024 | News

Sanofi and Teva Report Positive Phase 2b Results for Duvakitug in Ulcerative Colitis and Crohn’s Disease

Primary endpoints met in ulcerative colitis (UC) and Crohn’s disease (CD), the most common forms of inflammatory bowel disease (IBD) Primary endpo...

December 18, 2024 | News

Menarini Group Reports Positive Phase 3 Results for Obicetrapib in Reducing LDL-C Levels

– Both pivotal studies achieved primary endpoints of LS mean reduction in LDL-C on top of maximally tolerated lipid-modifying therapie...

December 17, 2024 | News

CHMP Endorses Celltrion’s Biosimilars Eydenzelt Stoboclo Osenvelt and Avtozma for Expanded Access to Biologic Treatments

The Committee for Medicinal Products for Human Use (CHMP) adopts positive opinions for Celltrion’s three biosimilar candidates – Eydenz...

December 16, 2024 | News

ADELA Phase III Trial Combines Elacestrant and Everolimus to Tackle Advanced ER+/HER2- Breast Cancer with ESR1 Mutations

ADELA, an international phase III study being conducted across multiple countries, combines elacestrant with everolimus to treat advanced ER+/HER2- breas...

December 13, 2024 | News

GNT Pharma Announces Promising Nelonemdaz Results, Initiates Global Phase 3 Stroke Trials

** IND submitted to the FDA showing significantly improved patient condition when administered within 70 minutes of arrival at the Emergency Room ** *Mult...

December 12, 2024 | News

Duke Street Bio Initiates Phase I Trial of Highly Selective PARP1 Inhibitor DSB2455 for Solid Tumours

Duke Street Bio Ltd, a precision medicine biotech developing next-generation small molecule cancer therapies, is pleased to announce that the first patient...

December 12, 2024 | News

Asahi Kasei Pharma Expands Global Reach with Exclusive Anti-CX3CR1 Antibody License

Asahi Kasei Pharma has taken another significant step toward becoming a leading global specialty pharmaceutical company by entering an exclusive license ag...

December 12, 2024 | News

Agilent Technologies Achieves EU IVDR Certification for PD-L1 IHC 28-8 pharmDx

-Agilent Technologies Inc. announced the issuing of a Class C companion diagnostic In Vitro Diagnostic Regulation (IVDR) certification for PD-L1...

December 11, 2024 | News

GHIT Fund and WHO Strengthen Partnership to Combat Neglected Tropical Diseases

The Global Health Innovative Technology (GHIT) Fund and the World Health Organization (WHO) have signed a memorandum of understanding (MoU) to furthe...

December 11, 2024 | News

Hansa Biopharma Completes Phase 3 Trial Enrollment Ahead of Schedule for Rare Autoimmune Disease

Hansa Biopharma, "Hansa" announced it has completed the enrolment of patients in the GOOD-IDES-02 trial, a global pivotal Phase 3 trial in anti-glomerular ...

December 06, 2024 | News

NTC Announces Positive Phase II Results for NTC014 in Bacterial Conjunctivitis Treatment

NTC, an international R&D focused pharmaceutical company headquartered in Italy, presents positive results from Phase II MIRAKLE study, a mul...

December 06, 2024 | News

QIAGEN Launches Industry-First Custom Digital PCR and NGS Panel Design Tools for Advanced Microbial Applications

QIAGEN introduces market’s first customizable digital PCR assay design tool with advanced design algorithms tailored for diverse microbial applicat...

November 29, 2024 | News

Vaxxas Expands Global Patent Portfolio to 42, Securing Exclusive Rights to HD-MAP Vaccination Technology

-Vaxxas, a clinical-stage biotechnology company, has expanded its global intellectual property portfolio to 42 patents, supporting its exclusive claim to m...

November 25, 2024 | News

Stay Connected